AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 102 filers reported holding AMYLYX PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,262,644 | -14.0% | 68,960 | +1.3% | 0.00% | -50.0% |
Q2 2023 | $1,468,809 | +65795.4% | 68,095 | -10.4% | 0.00% | -33.3% |
Q1 2023 | $2,229 | -15.7% | 75,962 | +6.1% | 0.00% | -25.0% |
Q4 2022 | $2,644 | -99.8% | 71,564 | +56.3% | 0.00% | +100.0% |
Q3 2022 | $1,289,000 | +313.1% | 45,793 | +183.1% | 0.00% | – |
Q2 2022 | $312,000 | – | 16,174 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Stonepine Capital Management, LLC | 2,515,868 | $46,065,543 | 15.30% |
Alpha Wave Global, LP | 853,262 | $15,623,227 | 9.88% |
Saturn V Capital Management LP | 886,143 | $16,225,278 | 6.79% |
Ally Bridge Group (NY) LLC | 272,690 | $4,992,954 | 5.86% |
Altium Capital Management LP | 534,700 | $9,790,357 | 5.11% |
Boxer Capital, LLC | 2,084,000 | $38,158,040 | 2.03% |
Octagon Capital Advisors LP | 695,000 | $12,725,450 | 1.96% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 295,000 | $5,398,500 | 1.82% |
Tri Locum Partners LP | 282,862 | $5,179,203 | 1.66% |
Perceptive Advisors | 2,688,873 | $49,233,265 | 1.64% |